Statistical Primer on Biosimilar Clinical Development.

Authors:
Isakov L; Jin B; Jacobs IA.

Journal:
Am J Ther

Publication Year: 2016

DOI:
10.1097/MJT.0000000000000391

PMCID:
PMC5102275

PMID:
26766293

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Am J Ther

Abbreviation: Am J Ther

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Therapeutics

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Predictors for Super-Responders in Cardiac Resynchronization Therapy.
Vătășescu RG; Târtea GC; Iorgulescu C and 6 more (2023) - Transparency Score: 2/6
Efficacy of Low-Dose Versus Traditional Buprenorphine Induction in the Hospital: A Quantitative and…
Sulakvelidze N; Ronan C; Peterkin AF and 1 more (2022) - Transparency Score: 3/6
Residual Disease After Primary Surgical Treatment for Advanced Epithelial Ovarian Cancer, Part 2: N…
Bryant A; Grayling M; Elattar A and 4 more (2022) - Transparency Score: 2/6
Residual Disease Threshold After Primary Surgical Treatment for Advanced Epithelial Ovarian Cancer,…
Bryant A; Johnson E; Grayling M and 6 more (2022) - Transparency Score: 3/6
Immune-Mediated Thrombocytopenia Associated With Ad26.COV2.S (Janssen; Johnson & Johnson) Vaccine.
Banerjee S; Sandhu M; Tonzi E and 2 more (2021) - Transparency Score: 1/6
View All Papers from This Journal
Transparency Score
2/6
0.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"All authors are employees of Pfizer and hold stock or stock options in Pfizer."

Evidence found in paper:

"Medical writing support was provided by Christina McManus, PhD of Engage Scientific Solutions and funded by Pfizer Inc."

Protocol Registration
Open Access
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025